Kidney cancer drug combo trial stopped early – what happened?
NCT ID NCT06114940
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two drugs (toripalimab and lenvatinib) given before and after kidney cancer surgery in people with different stages of kidney cancer. The goal was to see if the treatment could shrink or eliminate the tumor before surgery and keep cancer from coming back after. The trial was stopped early and included only 17 participants instead of the planned 69.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CLEAR CELL RENAL CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China
Nanjing, Jiangsu, 210000, China
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Two-Pronged immune attack shrink kidney tumors before surgery?
- Can a tracer that hunts unstable iron light up hidden tumors?
- Can a pill that starves tumors of oxygen help fight advanced cancer?
- Can fasting two days a week slow kidney cancer? a new trial tests the idea
- Drug cocktail aims to shrink kidney tumors before surgery and prevent return
- Smart bomb for kidney cancer: imaging and radiation combo targets tough tumors